Circulating endothelin-3 levels in patients with sickle cell disease during hydroxyurea treatment

Loading...
Thumbnail Image

Date

Authors

Makis, A. C.
Hatzimichael, E. C.
Kolios, G.
Bourantas, K. L.

Journal Title

Journal ISSN

Volume Title

Publisher

Abstract

Type of the conference item

Journal type

peer-reviewed

Educational material type

Conference Name

Journal name

Haematologica

Book name

Book series

Book edition

Alternative title / Subtitle

Description

Abnormal adhesion of red blood cells to the endothelium and the production of cytokines and vasoactive substances, such as endothelin-1 contribute to the pathogenesis of microvascular occlusion in sickle cell disease (SCD), even during the steady state. Endothelin-3 (ET-3) is a vasoconstrictive agent, which has not yet been studied in SCD.

Description

Keywords

Adult, Anemia, Sickle Cell/*blood/*drug therapy, Antisickling Agents/*therapeutic use, Endothelin-3/*blood, Female, Humans, Hydroxyurea/*therapeutic use, Male, Middle Aged

Subject classification

Citation

Link

http://www.ncbi.nlm.nih.gov/pubmed/15020278

Language

en

Publishing department/division

Advisor name

Examining committee

General Description / Additional Comments

Institution and School/Department of submitter

Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής

Table of contents

Sponsor

Bibliographic citation

Name(s) of contributor(s)

Number of Pages

Course details

Endorsement

Review

Supplemented By

Referenced By